THE ECONOMIC IMPACT OF REDUCING BLEEDING WITH EMICIZUMAB IN PATIENTS WITH HEMOPHILIA A AND FACTOR VIII INHIBITORS - BRAZILIAN CASE

被引：0
|
作者：
Segre, N. [1 ]
Mata, V [1 ]
Martins, T. D. C. [1 ]
机构：
[1] F Hoffmann La Roche, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE559
引用
收藏
页码：S165 / S165
页数：1
相关论文
共 50 条
  • [1] Emicizumab for hemophilia A with factor VIII inhibitors
    Young, Guy
    Callaghan, Michael
    Dunn, Amy
    Kruse-Jarres, Rebecca
    Pipe, Steven
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (11) : 835 - 846
  • [2] The economic impact of factor VIII inhibitors in patients with hemophilia.
    Bohn, RL
    Aledort, LM
    Putnam, KG
    Ewenstein, BM
    Avorn, J
    [J]. BLOOD, 2000, 96 (11) : 434A - 435A
  • [3] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [4] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
    Shima, Midori
    [J]. JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
  • [5] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [6] EMICIZUMAB IS COST-SAVING FOR FINNISH HEMOPHILIA A PATIENTS WITH FACTOR VIII INHIBITORS
    Viita, A. M.
    Conejero, Prada E.
    Laine, J.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S98 - S98
  • [7] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Fredrik Jonsson
    Christophe Schmitt
    Claire Petry
    Francois Mercier
    Nicolas Frey
    Sylvie Retout
    [J]. Clinical Pharmacokinetics, 2021, 60 : 931 - 941
  • [8] Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors
    Watanabe, Alexandre Hikiji
    Lee, Shaun Wen Huey
    Chai-Adisaksopha, Chatree
    Lim, Ming Y.
    Chaiyakunapruk, Nathorn
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 7 - 13
  • [9] Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
    Jonsson, Fredrik
    Schmitt, Christophe
    Petry, Claire
    Mercier, Francois
    Frey, Nicolas
    Retout, Sylvie
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 931 - 941
  • [10] Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab
    Miller, Connie H.
    Boylan, Brian
    Payne, Amanda B.
    Driggers, Jennifer
    Bean, Christopher J.
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : E84 - E86
12345